<DOC>
	<DOCNO>NCT02384382</DOCNO>
	<brief_summary>The purpose study evaluate 18F-sodium fluoride positron-emission tomography / compute tomography ( 18F-NaF PET/CT ) image method determine treatment response metastatic bone lesion patient receive enzalutamide castration-resistant prostate cancer .</brief_summary>
	<brief_title>A Positron Emission Tomography/Computed Tomography ( PET/CT ) Bone Imaging Study Patients Receiving Enzalutamide Castration-Resistant Prostate Cancer ( CRPC )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate without neuroendocrine differentiation , signet cell small cell feature ; Presence bone metastatic disease assess least two lesion whole body metastable technetiummethylene diphosphonate ( 99mTcMDP ) bone scintigraphy ; Throughout study , ongoing androgen deprivation therapy luteinizing hormonereleasing hormone ( LHRH ) analogue prior bilateral orchiectomy ( medical surgical castration ) ; Testosterone ≤ 1.73 nmol/L ( ≤ 50 ng/dL ) screening ; Progressive disease androgen deprivation therapy screening define minimum two sequentially rise prostatespecific antigen ( PSA ) value ( PSA1 &lt; PSA2 &lt; PSA3 ) ; The screening PSA ( PSA3 ) must ≥ 2 μg/L ( ≥ 2 ng/mL ) . Prior enzalutamide , abiraterone acetate , aminoglutethimide , ketoconazole , radium Ra 223 dichloride bonetargeting radionuclides , cytotoxic chemotherapy CRPC set treatment prostate cancer participation clinical trial investigational agent inhibits androgen receptor androgen synthesis ( unless treatment placebo ) ; Treatment hormonal therapy ( eg , androgen receptor inhibitor , 5alpha reductase inhibitor ) biologic therapy prostate cancer ( LHRH analogue therapy ) within 4 week enrollment ; Initiation new treatment denosumab , bisphosphonates , systemic corticosteroid treatment prostate cancer within 4 week enrollment ; Use investigational agent within 4 week screen visit ; Radiation therapy bone within 4 week enrollment ; Use opiate analgesic prostate cancer pain within 4 week enrollment ; Screening 99mTcMDP bone scintigraphy show superscan ; Visceral ( eg , lung , liver ) metastatic disease . Adenopathy allow ; Current previously treat brain metastasis active leptomeningeal disease ; History seizure time past reason condition may predispose seizure .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cancer Prostate</keyword>
</DOC>